Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial

No abstract is available for this paper.

• Publication year

  2012

• Venue

  International Journal of Clinical Oncology

• Publication date

  2012-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10147-011-0331-2PMID 22002492
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study

  2023cited by this paper
• Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).

  2010cited by this paper
• Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.

  2008cited by this paper
• Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.

  2007cited by this paper
• Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

  2007cited by this paper
• Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer

  2006cited by this paper
• Survival of cancer patients diagnosed between 1993 and 1996: a collaborative study of population-based cancer registries in Japan.

  2006influential reference
• Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

  2005cited by this paper
• National Cancer Institute-Common Toxicity Criteria(NCI-CTC Version 2.0） 日本語訳JCOG版の信頼性の検討

  2004cited by this paper
• Pathology: Cancer cells compress intratumour vessels

  2004cited by this paper
• FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Cancer Statistics, 2004

  2004cited by this paper
• The biology of VEGF and its receptors

  2003cited by this paper
• Global cancer statistics in the year 2000.

  2001cited by this paper
• Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper

• Natural Compounds Targeting the Autophagy Pathway in the Treatment of Colorectal Cancer

  2023cites this paper
• Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer

  2022cites this paper
• Serious Adverse Events Reporting in Phase III Randomized Clinical Trials of Colorectal Cancer Treatments: A Systematic Analysis

  2021cites this paper
• Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice

  2021cites this paper
• Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review

  2020cites this paper
• The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls

  2020cites this paper
• Natural products for treating colorectal cancer: A mechanistic review.

  2019cites this paper
• Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS

  2018cites this paper
• Survival in signet ring cell carcinoma varies based on primary tumor location: a Surveillance, Epidemiology, and End Results database analysis

  2018cites this paper
• Lack of pharmacokinetic drug–drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors

  2016cites this paper
• Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801)

  2016cites this paper
• Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)

  2015cites this paper
• Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.

  2015cites this paper
• Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study.

  2014cites this paper
• Estudios farmacogenéticos en el cáncer colorrectal: la vía del receptor del factor de crecimiento epidérmico

  2014cites this paper
• A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer

  2014cites this paper
• Methods of overcoming treatment resistance in colorectal cancer.

  2014cites this paper
• Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma

  2014cites this paper
• Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study

  2013cites this paper
• Safety and Efficacy of Modified FOLFOX6 plus High-Dose Bevacizumab in Second-Line or Later Treatment of Patients with Metastatic Colorectal Cancer

  2013cites this paper
• FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials

  2013cites this paper
• Managing toxicities associated with antiangiogenic biologic agents in combination with chemotherapy for metastatic colorectal cancer.

  2013cites this paper
• Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management.

  2013cites this paper
• Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy

  2013cites this paper
• Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer

  2012cites this paper
• The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab

  2012cites this paper